The efficacy and safety of remimazolam besylate, ciprofol, and propofol during hysteroscopy
ObjectiveRemimazolam besylate and Ciprofol are newer sedatives used in minor surgeries. Propofol is a classic drug mainly used for short surgeries. This trial was conducted to compare the efficacy and safety of remimazolam besylate, ciprofol, and propofol during hysteroscopic surgeries.MethodsPatien...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1427755/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841555125885206528 |
|---|---|
| author | Weifeng Shan Shuying Gao Mengting Ai Haiyan Lan Gongchen Duan Xiaoli Dong Qiaomin Xu Yini Wu Jimin Wu |
| author_facet | Weifeng Shan Shuying Gao Mengting Ai Haiyan Lan Gongchen Duan Xiaoli Dong Qiaomin Xu Yini Wu Jimin Wu |
| author_sort | Weifeng Shan |
| collection | DOAJ |
| description | ObjectiveRemimazolam besylate and Ciprofol are newer sedatives used in minor surgeries. Propofol is a classic drug mainly used for short surgeries. This trial was conducted to compare the efficacy and safety of remimazolam besylate, ciprofol, and propofol during hysteroscopic surgeries.MethodsPatients undergoing hysteroscopy were randomly assigned to receive remimazolam besylate (Group R), ciprofol (Group C), or propofol (Group P). A total of 194 patients were assessed for eligibility. One patient in Group P was excluded because the operation had timed out of 60 min. Patients all in Group R、Group C and Group P received an induction dose of 0.2 mg/kg remimazolam besylate、0.4 mg/kg ciprofol、2.0 mg/kg propofol seperately over 30 s. A corresponding dosage of 1 mg/kg/h、0.6–1.2 mg/kg/h and 3.0–6.0 mg/kg/h was given by continuous intravenous infusion to maintain a BIS of 40–60 till the end of the surgery. The incidence rates of body movement, respiratory depression, and adverse effects were compared among the groups.ResultsThe incidence of injection pain was much higher in Group P (64.1%) than that in Group R (3.4%) and Group C (3.2%, both P < 0.001). The onset time was significantly shorter in Group P than that in Group R and Group C (both P < 0.01). The awakening time (MOAA/S score = 3) was longest in Group R, followed by Groups C and Group P (P < 0.01). The time to complete recovery (MOAA/S score = 5) has no significantly difference between Group C and Group P, whereas the onset time was significantly shorter in Group R (P < 0.01). The number of body movements was significantly higher in Group R than that in Group C and Group P (P < 0.01). The incidence of hypotension was significantly lower in Group R than that in Group C and Group P (both P < 0.01). The rate of respiratory inhibition was significantly lower in Group R and Group C than that in Group P (both P < 0.05).ConclusionConsidering jointly the safety and efficacy, ciprofol seems to be the best choice for sedation. |
| format | Article |
| id | doaj-art-eb82181afa92495f93407956393a91ae |
| institution | Kabale University |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-eb82181afa92495f93407956393a91ae2025-01-08T06:11:53ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-01-011510.3389/fphar.2024.14277551427755The efficacy and safety of remimazolam besylate, ciprofol, and propofol during hysteroscopyWeifeng ShanShuying GaoMengting AiHaiyan LanGongchen DuanXiaoli DongQiaomin XuYini WuJimin WuObjectiveRemimazolam besylate and Ciprofol are newer sedatives used in minor surgeries. Propofol is a classic drug mainly used for short surgeries. This trial was conducted to compare the efficacy and safety of remimazolam besylate, ciprofol, and propofol during hysteroscopic surgeries.MethodsPatients undergoing hysteroscopy were randomly assigned to receive remimazolam besylate (Group R), ciprofol (Group C), or propofol (Group P). A total of 194 patients were assessed for eligibility. One patient in Group P was excluded because the operation had timed out of 60 min. Patients all in Group R、Group C and Group P received an induction dose of 0.2 mg/kg remimazolam besylate、0.4 mg/kg ciprofol、2.0 mg/kg propofol seperately over 30 s. A corresponding dosage of 1 mg/kg/h、0.6–1.2 mg/kg/h and 3.0–6.0 mg/kg/h was given by continuous intravenous infusion to maintain a BIS of 40–60 till the end of the surgery. The incidence rates of body movement, respiratory depression, and adverse effects were compared among the groups.ResultsThe incidence of injection pain was much higher in Group P (64.1%) than that in Group R (3.4%) and Group C (3.2%, both P < 0.001). The onset time was significantly shorter in Group P than that in Group R and Group C (both P < 0.01). The awakening time (MOAA/S score = 3) was longest in Group R, followed by Groups C and Group P (P < 0.01). The time to complete recovery (MOAA/S score = 5) has no significantly difference between Group C and Group P, whereas the onset time was significantly shorter in Group R (P < 0.01). The number of body movements was significantly higher in Group R than that in Group C and Group P (P < 0.01). The incidence of hypotension was significantly lower in Group R than that in Group C and Group P (both P < 0.01). The rate of respiratory inhibition was significantly lower in Group R and Group C than that in Group P (both P < 0.05).ConclusionConsidering jointly the safety and efficacy, ciprofol seems to be the best choice for sedation.https://www.frontiersin.org/articles/10.3389/fphar.2024.1427755/fullremimazolamciprofolpropofolhysteroscopyefficacysafety |
| spellingShingle | Weifeng Shan Shuying Gao Mengting Ai Haiyan Lan Gongchen Duan Xiaoli Dong Qiaomin Xu Yini Wu Jimin Wu The efficacy and safety of remimazolam besylate, ciprofol, and propofol during hysteroscopy Frontiers in Pharmacology remimazolam ciprofol propofol hysteroscopy efficacy safety |
| title | The efficacy and safety of remimazolam besylate, ciprofol, and propofol during hysteroscopy |
| title_full | The efficacy and safety of remimazolam besylate, ciprofol, and propofol during hysteroscopy |
| title_fullStr | The efficacy and safety of remimazolam besylate, ciprofol, and propofol during hysteroscopy |
| title_full_unstemmed | The efficacy and safety of remimazolam besylate, ciprofol, and propofol during hysteroscopy |
| title_short | The efficacy and safety of remimazolam besylate, ciprofol, and propofol during hysteroscopy |
| title_sort | efficacy and safety of remimazolam besylate ciprofol and propofol during hysteroscopy |
| topic | remimazolam ciprofol propofol hysteroscopy efficacy safety |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2024.1427755/full |
| work_keys_str_mv | AT weifengshan theefficacyandsafetyofremimazolambesylateciprofolandpropofolduringhysteroscopy AT shuyinggao theefficacyandsafetyofremimazolambesylateciprofolandpropofolduringhysteroscopy AT mengtingai theefficacyandsafetyofremimazolambesylateciprofolandpropofolduringhysteroscopy AT haiyanlan theefficacyandsafetyofremimazolambesylateciprofolandpropofolduringhysteroscopy AT gongchenduan theefficacyandsafetyofremimazolambesylateciprofolandpropofolduringhysteroscopy AT xiaolidong theefficacyandsafetyofremimazolambesylateciprofolandpropofolduringhysteroscopy AT qiaominxu theefficacyandsafetyofremimazolambesylateciprofolandpropofolduringhysteroscopy AT yiniwu theefficacyandsafetyofremimazolambesylateciprofolandpropofolduringhysteroscopy AT jiminwu theefficacyandsafetyofremimazolambesylateciprofolandpropofolduringhysteroscopy AT weifengshan efficacyandsafetyofremimazolambesylateciprofolandpropofolduringhysteroscopy AT shuyinggao efficacyandsafetyofremimazolambesylateciprofolandpropofolduringhysteroscopy AT mengtingai efficacyandsafetyofremimazolambesylateciprofolandpropofolduringhysteroscopy AT haiyanlan efficacyandsafetyofremimazolambesylateciprofolandpropofolduringhysteroscopy AT gongchenduan efficacyandsafetyofremimazolambesylateciprofolandpropofolduringhysteroscopy AT xiaolidong efficacyandsafetyofremimazolambesylateciprofolandpropofolduringhysteroscopy AT qiaominxu efficacyandsafetyofremimazolambesylateciprofolandpropofolduringhysteroscopy AT yiniwu efficacyandsafetyofremimazolambesylateciprofolandpropofolduringhysteroscopy AT jiminwu efficacyandsafetyofremimazolambesylateciprofolandpropofolduringhysteroscopy |